Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma.
about
Metabolic Profiling of the Novel Hypoxia-Inducible Factor 2α Inhibitor PT2385 In Vivo and In Vitro.Renal cell carcinoma: a review of biology and pathophysiology.VHL and Hypoxia Signaling: Beyond HIF in Cancer.Treatment for Patients With Malignant Pheochromocytomas and Paragangliomas: A Perspective From the Hallmarks of Cancer.PHD2 inactivation in Type I cells drives HIF-2α-dependent multilineage hyperplasia and the formation of paraganglioma-like carotid bodies
P2860
Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Phase I Dose-Escalation Trial ...... ear Cell Renal Cell Carcinoma.
@en
Phase I Dose-Escalation Trial ...... ear Cell Renal Cell Carcinoma.
@nl
type
label
Phase I Dose-Escalation Trial ...... ear Cell Renal Cell Carcinoma.
@en
Phase I Dose-Escalation Trial ...... ear Cell Renal Cell Carcinoma.
@nl
prefLabel
Phase I Dose-Escalation Trial ...... ear Cell Renal Cell Carcinoma.
@en
Phase I Dose-Escalation Trial ...... ear Cell Renal Cell Carcinoma.
@nl
P2093
P2860
P356
P1476
Phase I Dose-Escalation Trial ...... ear Cell Renal Cell Carcinoma.
@en
P2093
Ann M Lowe
Brian I Rini
Elaine T Lam
Eli M Wallace
James Brugarolas
Jeffrey R Infante
John A Josey
Keshi Wang
Kevin D Courtney
Naseem J Zojwalla
P2860
P304
JCO2017742627
P356
10.1200/JCO.2017.74.2627
P407
P577
2017-12-19T00:00:00Z